Theoretical considerations suggest Retatrutides triple-agonist mechanism might produce more robust effects on reward circuitry, similar to its enhanced weight loss efficacy compared to single-agonist medications
Another large-scale cohort study demonstrated that long-term GLP-1RA use was associated with a more than twofold, exposure-dependent increase in the risk of developing nAMD
Eli Lilly and Company said this week it will seek approval for retatrutide, an injection that in trials has taken off more body weight than any obesity drug before it
It may mean building a realistic plan for walking, resistance training, mobility, or physical therapy when appropriate
People who significantly decrease their weight - whether through GLP-1s, behavioral programs or bariatric surgery - often lose muscle mass at the same time
Unfortunately, for some people, this can result in super negative side effects like nausea, vomiting, and diarrhea - one study reported that 50% of patients taking GLP-1 agonists experienced nausea while taking them
